title: A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor.
authors.affiliation: Merck Research Laboratories, Rahway, New Jersey 07065.
authors.forename: S E
authors.initials: SE
authors.lastname: de Laszlo
authors.forename: C S
authors.initials: CS
authors.lastname: Quagliato
authors.forename: W J
authors.initials: WJ
authors.lastname: Greenlee
authors.forename: A A
authors.initials: AA
authors.lastname: Patchett
authors.forename: R S
authors.initials: RS
authors.lastname: Chang
authors.forename: V J
authors.initials: VJ
authors.lastname: Lotti
authors.forename: T B
authors.initials: TB
authors.lastname: Chen
authors.forename: S A
authors.initials: SA
authors.lastname: Scheck
authors.forename: K A
authors.initials: KA
authors.lastname: Faust
authors.forename: S S
authors.initials: SS
authors.lastname: Kivlighn
mesh_terms: D000284:Administration, Oral; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001665:Binding Sites; D011799:Quinazolines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011945:Receptors, Angiotensin / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D057911:Angiotensin Receptor Antagonists; D011799:Quinazolines; D011945:Receptors, Angiotensin; D000804:Angiotensin II